Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies

Menopause

Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis

Obstet Gynecol

Menegaz de Almeida A, Oliveira P, Lopes L, Leite M, Morbach V, Alves Kelly F, Barros Í, Aquino de Moraes FC, Prevedello A

doi: 10.1097/AOG.0000000000005812

Endometriosis

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)

Hum Reprod

Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A, Paszkowski M, Petraglia F, Renner SP, Patel A, Boolell M, Bestel E, Dolmans MM

doi: 10.1093/humrep/deae076

Reproductive Health

Efficacy and safety of estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg combination in a cyclic regimen for the treatment of primary and secondary dysmenorrhea: A multicenter, placebo-controlled, double-blind, randomized study

Fertil Steril

Osuga Y, Kobayashi T, Hirakawa A, Takayanagi T, Nogami M, Tayzar K, Mochiyama T, Hirayama M, Foidart JM, Harada T

doi: 10.1016/j.fertnstert.2024.11.003

Benign Prostatic Hyperplasia (BPH)

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial

J Urol

Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S

doi: 10.1097/JU.0000000000003999

Endometriosis

Efficacy and safety of estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg combination in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: A multicenter, placebo-controlled, double-blind, randomized study

Fertil Steril

Harada T, Kobayashi T, Hirakawa A, Takayanagi T, Nogami M, Mochiyama T, Hirayama M, Foidart JM, Osuga Y

doi: 10.1016/j.fertnstert.2024.07.011

Further Publications Gynecology

Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder

J Sex Med

Thurman AR, Johnson I, Cornell KA, Hatheway J, Kim NN, Parish SJ, Dart C, Friend DR, Goldstein A

doi: 10.1093/jsxmed/qdae089

Overactive BladderUrinary Incontinence

Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial

J Urol

Enemchukwu EA, Kalota S, Robertson K, Ge S, Lu J, Badger H, Mujais S, Peters KM

doi: 10.1097/JU.0000000000004373

Further Publications Urology

Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

Eur Urol

Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T

doi: 10.1016/j.eururo.2024.03.015

Uro-Oncology

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study